Ellen M Carl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2840755/publications.pdf

Version: 2024-02-01

52 papers	1,679 citations	23 h-index	288905 40 g-index
52	52	52	2139
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. Journal of Neuroinflammation, 2011, 8, 127.	3.1	186
2	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. Neurolmage, 2012, 59, 331-339.	2.1	176
3	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. Radiology, 2013, 268, 831-841.	3.6	145
4	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310051.	0.9	95
5	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. BMC Medicine, 2011, 9, 22.	2.3	77
6	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology, 2018, 289, 487-496.	3.6	75
7	Iron deposition in multiple sclerosis lesions measured by susceptibilityâ€weighted imaging filtered phase: A case control study. Journal of Magnetic Resonance Imaging, 2012, 36, 73-83.	1.9	60
8	Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 36-42.	1.4	53
9	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurology, 2011, 11, 128.	0.8	50
10	Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology, 2014, 83, 441-449.	1.5	43
11	Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers. PLoS ONE, 2011, 6, e28062.	1.1	40
12	Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e190.	3.1	39
13	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1075-1081.	0.9	36
14	Aging and Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 527-535.	1.0	33
15	Changes of Cine Cerebrospinal Fluid Dynamics in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study. Journal of Vascular and Interventional Radiology, 2013, 24, 829-838.	0.2	31
16	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. Journal of Magnetic Resonance Imaging, 2014, 40, 1215-1222.	1.9	31
17	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. Journal of Alternative and Complementary Medicine, 2018, 24, 596-602.	2.1	31
18	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 15-28.	1.5	29

#	Article	IF	CITATIONS
19	Patterns of dietary and herbal supplement use by multiple sclerosis patients. Journal of Neurology, 2012, 259, 637-644.	1.8	29
20	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 567-576.	1.4	28
21	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Multiple Sclerosis Journal, 2020, 26, 322-332.	1.4	28
22	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. Journal of Neuroimmunology, 2012, 243, 61-68.	1.1	27
23	Comparison of Intravascular Ultrasound with Conventional Venography for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency. Journal of Vascular and Interventional Radiology, 2013, 24, 1487-1498.e1.	0.2	25
24	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. American Journal of Neuroradiology, 2018, 39, 2237-2242.	1.2	25
25	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Frontiers in Bioscience - Elite, 2013, E5, 525-532.	0.9	24
26	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	1.1	21
27	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.3	20
28	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. Journal of Clinical Medicine, 2019, 8, 344.	1.0	17
29	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. Neurological Research, 2012, 34, 819-827.	0.6	16
30	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurology, 2012, 12, 26.	0.8	15
31	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study. BMC Neurology, 2013, 13, 151.	0.8	15
32	Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 937-943.	0.9	15
33	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. Journal of the Neurological Sciences, 2018, 388, 175-181.	0.3	15
34	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice—The MSâ€MRIUS Study. Journal of Neuroimaging, 2017, 27, 339-347.	1.0	14
35	The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing–Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. CNS Drugs, 2018, 32, 763-770.	2.7	14
36	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e16802.	1.1	14

#	Article	IF	CITATIONS
37	The Emerging Global Tobacco Treatment Workforce: Characteristics of Tobacco Treatment Specialists Trained in Council-Accredited Training Programs from 2017 to 2019. International Journal of Environmental Research and Public Health, 2021, 18, 2416.	1.2	13
38	Jugular Venous Flow Quantification Using Doppler Sonography. Ultrasound in Medicine and Biology, 2018, 44, 1762-1769.	0.7	12
39	Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center. International Journal of Environmental Research and Public Health, 2020, 17, 3907.	1.2	12
40	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. Neurological Research, 2012, 34, 793-801.	0.6	8
41	Effect of switching from glatiramer acetate 20â€mg/daily to glatiramer acetate 40â€mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. Journal of the Neurological Sciences, 2018, 387, 152-156.	0.3	7
42	Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097075.	1.5	7
43	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Multiple Sclerosis and Related Disorders, 2019, 27, 65-73.	0.9	6
44	Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis. BMC Medicine, 2013, 11, 167.	2.3	5
45	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2015, 8, 59-70.	1.5	5
46	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsingâ€"remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. Journal of Neuroimmunology, 2015, 281, 44-50.	1.1	3
47	Future Thinking Priming Especially Effective at Modifying Delay Discounting Rates among Cigarette Smokers. International Journal of Environmental Research and Public Health, 2021, 18, 8717.	1.2	3
48	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. Clinical Neurology and Neurosurgery, 2013, 115, S49-S54.	0.6	2
49	Internal Validity of Two Promising Methods of Altering Temporal Orientation among Cigarette Smokers. International Journal of Environmental Research and Public Health, 2021, 18, 12601.	1.2	2
50	Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. International Journal of Molecular Sciences, 2012, 13, 5659-5673.	1.8	1
51	Increasing Physical Activity among Breast Cancer Survivors by Modulating Temporal Orientation with rTMS: Feasibility and Potential Efficacy. International Journal of Environmental Research and Public Health, 2021, 18, 10052.	1.2	1
52	Methodological Investigation of Time Perspective Scoring and Quality of Life among Individuals with Multiple Sclerosis. International Journal of Environmental Research and Public Health, 2022, 19, 5038.	1.2	0